Endometrial Cancer

The addition of pembrolizumab to chemotherapy as adjuvant therapy did not confer significant improvement in DFS compared with placebo in women with newly diagnosed, high-risk endometrial cancer.

Outcomes of using menopausal hormone therapy beyond age 65 years varied based on hormone therapy types, administration and strengths among women on Medicare, researchers reported in Menopause.

Asian, Black and Hispanic women with gynecologic cancers had a lower likelihood of being enrolled in clinical trials compared with white women, according to study findings published in JAMA Network Open.

A regimen containing dostarlimab plus standard-of-care chemotherapy significantly improved OS compared with chemotherapy alone in women with primary advanced or recurrent endometrial cancer, according to the agent’s manufacturer.

In the first years of use, women prescribed conjugated estrogens/bazedoxifene vs. estrogen/progestin for menopausal symptoms may have higher rates of endometrial cancer and endometrial hyperplasia but lower breast cancer rates.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about combining different therapeutic modalities for advanced endometrial cancer.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about current and emerging prognostic biomarkers of endometrial cancer.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about treatment options for advanced recurrent endometrial cancer.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about recent advancements in endometrial cancer.